Combination therapy could treat tumors resistant to MAPK pathway inhibitors

In a study published in Nature Medicine, Genmab A/S (CSE:GEN; Pink:GMXAY) and academic researchers identified a combination therapy approach that could combat drug resistance in heterogeneous tumors.

Melanoma tumors with BRAF mutations that are -- or become -- resistant to BRAF and MEK inhibitor therapies often express AXL receptor tyrosine kinase (AXL;UFO), while tumors with low AXL expression are generally sensitive to the drugs. In this study, researchers used Genmab's antibody-drug conjugate (ADC), called HuMax-AXL-ADC, to target AXL-positive cancer cells as monotherapy and in combination with BRAF and MEK inhibitors...